VP, TTR Franchise Head
Posted on: November 15, 2023
Work_Category - hybrid Description Overview
The Vice President, TTR Franchise Head is a pivotal role that will
be responsible for program/asset leadership and all aspects of
global commercialization for our transthyretin (TTR) amyloidosis
franchise, currently comprised of Onpattro, Amvuttra, and
ALN-TTR-sc04 (a next-generation compound currently in development).
The multi-billion-dollar TTR market is projected to grow
significantly in the next several years with the entry of multiple
players. The Vice President, TTR Franchise Head, in close
collaboration with the cross-functional leaders of all relevant
functions (e.g. Clinical Development, Regulatory, Drug Safety,
Manufacturing, Commercial, Medical Affairs), will ensure optimal
development and commercial success of all TTR assets, including
clinical development planning, pre/launch planning (including
global brand strategy, positioning, and messaging), competitive
awareness/readiness, and life-cycle planning. Additionally, the
Vice President, TTR Franchise Head will work closely with regions
and key markets to understand regional/local commercial dynamics in
order to drive commercial success of launches and ongoing success
of in-market medicines.
The ideal candidate will be a strategic leader versed in driving
cross-region, cross-functional commercial success, and ideally with
experience in drug development, in-country/region
commercialization, and matrix leadership. S/he will be a strong
influencer with a competitive mindset who can integrate multiple
perspectives effectively and align stakeholders across different
functions and levels of the organization.
This will be a highly visible role, interacting extensively with
the heads of all key functions at Alnylam, as well as the Executive
Leadership Team (ELT / C-suite) and the Board of Directors.
This role will report to the Senior Vice President of Global
This position is onsite / hybrid onsiteand will be primarily
located at Alnylam headquarters in Cambridge, MA.
- Lead the TTR Global Franchise program/asset team and global
marketing team, and serve as the single point of accountability for
all things spanning the development and commercialization of
Alnylam's TTR franchise.
- Collaborate closely with leaders and colleagues from Clinical
Development functions, including Clinical Operations, Regulatory,
Statistics, and Drug Safety to optimize and accelerate clinical
development plans, prepare for data readouts, and engage with
regulatory agencies in study planning and label
- Collaborate closely with leaders and colleagues from TOQ
(Technical Operations & Quality) in planning for TTR studies,
bringing TTR medicines to market, and manufacturing/distributing
adequate and reliable supply for in-market TTR medicines.
- Lead Global Marketing for the TTR franchise, and collaborate
closely with key Global Commercial functions including Pricing &
Market Access, Insights & Analytics, and Launch Excellence, as well
as Global Medical Affairs, and regional/country colleagues, to
build and optimize launch and commercialization strategies that are
highly competitive and deliver lasting impact.
- Oversee development/refinement of annual objectives for the
Global TTR Franchise, annual strategic and tactical plans for TTR
marketed (or pre-launch) brands, and the life-cycle management plan
for the TTR franchise.
- Oversee proactive monitoring of competitor activities including
competitor studies, data readouts, and investor/analyst
engagements, and provide interpretation/implication of these
competitor activities for Alnylam's TTR Franchise.
- Work closely with Corporate Communications to shape and refine
external messaging for the TTR Franchise to be used by Alnylam
senior leadership in investor conferences, quarterly earnings
calls, and analyst meetings.
- Cultivate relationships with the top experts, Key Opinion
Leaders, and patient advocates in the treatment of ATTR amyloidosis
to ensure all aspects of planning include a strong external
- Lead a team of 4-6 direct reports (which is expected to grow)
and cultivate a culture of bold and innovative thinking, purposeful
urgency, a passion for excellence, and a commitment to developing
- Deep understanding of, and experience with, global and
regional/country product commercialization in highly competitive
markets with medium to large-sized patient populations. Deep US
market experience is a must. Experience in drug development and
global product registration is a plus.
- Ability to influence cross-functionally and drive alignment
within the team, with peers, and with senior management.
Demonstratable level of executive presence.
- Ability to operate at both the strategic and tactical level,
with the ability to seamlessly move between both
- Proactive "hands-on" individual with collaborative orientation,
who manages matrix teams effectively, is very self-motivated, and
can smoothly establish and sustain strong working relationships
within both internal and external organizations and
- Strong patient/physician/market-centricity that is infused in
discussions and decision-making.
- Initiative and independence to identify short and long-term
program needs, creatively formulate plans with team input,
efficiently achieve timely decisions/alignment, and organize and
- Exceptional written and verbal communication skills. Ability to
articulate program vision and motivate the team; communicates in an
open, direct, and timely manner; ensures broader organization is
aligned with and aware of the program strategy, status, and
- Decisive as well as collaborative. Can flex when needed and
pursues data-driven decisions.
- BA/BS degree required; advanced scientific or business degree
- 10+ years of varied biopharmaceutical or related experience,
including global/international matrix team responsibilities.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of
RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and more prevalent diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach to treating diseases at their genetic
source by "interfering" with mRNA that cause or contribute to
disease. Since our founding in 2002, Alnylam has led the RNAi
Revolution and continues to turn scientific possibility into
Our people-first culture is guided by our core values: fiercely
innovative, open culture, purposeful urgency, passion for
excellence, and commitment to people, and these values influence
how we work and the business decisions we make. Thanks to feedback
from our employees over the years, we've been fortunate to be named
a top employer around the world. Alnylam is extremely proud to have
been recognized as the #1 Large Employer by Boston Globe Top Places
to Work in 2022, one of Science Magazine's Top Biopharma Employers,
one of America's Most Responsible Companies for 2023 by Newsweek, a
Fast Company Best Workplace for Innovators, and a Great Place to
Work in Canada, France, Italy, Spain, Switzerland, and UK - among
At Alnylam, we commit to an inclusive recruitment process and equal
employment opportunity. We are dedicated to building an environment
where employees can feel that they belong, can bring their
authentic selves to work, and achieve to their full potential. By
empowering employees to embrace their unique differences at work,
our business grows stronger with advanced and original thinking,
allowing us to bring groundbreaking medicines to patients.
Qualified applicants will receive consideration for employment
without regard to their race, color, religion, age, sex, sexual
orientation, gender identity or expression, national origin,
ethnicity, marital status, protected veteran status, disability, or
any other characteristics prohibited by law. Alnylam is an E-Verify
Keywords: Alnylam, Cambridge , VP, TTR Franchise Head, Executive , Cambridge, Massachusetts
Didn't find what you're looking for? Search again!